Platelet glycoprotein IIb/IIIa receptor antagonists and their use in elderly patients

Drugs and Aging

Volumn 16, Issue 3, 2000, Pages 179-187

  Mak, Koon Hou ^a   Effron, Mark B ^b   Moliterno, David J ^b  

^a TAN TOCK SENG HOSPITAL   (Singapore)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ANTITHROMBOCYTIC AGENT; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; TIROFIBAN;

AGED; CLINICAL TRIAL; CORONARY ARTERY DISEASE; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION;

EID: 0034065548     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200016030-00003     Document Type: Review

References (26)

1. 1. World Health Organization (WHO). Fifty facts from the World Health Report 1998: life in the 21st century - a vision for all [online]. Available from: URL: http://www.who.org/whr/ 1998/factse.html [Accessed 1999 Dec 10]
2. 2. American Heart Association. The National Health and Nutrition Examination III: National Center for Health Statistics and the American Heart Association [online]. URL: http:// www.americanheart.org/statistics/03cardio.html [Accessed Jan 2000]
3. 3. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106
4. 4. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy II: maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ 1994; 308: 159-68
5. 5. Krumholz HM, Radford MJ, Ellerheck EF, et al. Aspirin in the treatment of acute myocardial infarction in elderly Medicare beneficiaries: patterns of use and outcomes. Circulation 1995; 92: 2841-7
6. 6. Coller BS, Peerschke EI, Scudder LE, et al. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thromasthenic-like state in normal platelets and binds to glycoprotein IIb and/or IIIa. J Clin Invest 1983; 72: 325-38
7. 7. Mak KH, Topol EJ. Platelet glycoprotein IIb/IIIa inhibitors for acute coronary syndromes and percutaneous coronary intervention.In: Topol EJ, editor. Textbook of interventional cardiology. Philadelphia: WB Saunders, 1996: 345-62
8. 8. Topol EJ. Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence. Circulation 1998; 97: 211-8
9. 9. EPIC Investigators. Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk patients. N Engl J Med 1994; 330: 956-61
10. 10. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994; 343: 881-6
11. 11. Topol EJ, Ferguson JJ, Weisman HF, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. JAMA 1997; 278: 479-84
12. 12. CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997; 349: 1429-35
13. 13. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-96
14. 14. EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998; 352: 87-92
15. 15. Impact-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997; 349: 1422-8
16. 16. PURSUIT Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436-43
17. 17. RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary, angioplasty. Circulation 1997; 96: 1445-53
18. 18. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338: 1488-97
19. 19. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338: 1498-1505
20. 20. Bovill EG, Terrin ML, Stump DC, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Ann Intern Med 1991; 115:256-65
21. 21. Aguirre FV, Topol EJ, Ferguson JJ, et al. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation 1995; 91: 2882-90
22. 22. Lincoff A, Tcheng J, Califf R, et al. Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization: PROLOG Investigators. Am J Cardiol 1997; 79: 286-91
23. 23. Simpfendorfer C, Kottke-Marchant K, Lowrie M, et al. First chimeric platelet glycoprotein IIb/IIIa integrin blockade: a randomized, placebo-controlled pilot study of Xemilofiban in unstable angina with percutaneous coronary intervention. Circulation 1997; 96: 76-81
24. 24. Kereiakes DJ, Kleiman N, Ferguson JJ, et al. Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment. Circulation 1997; 96: 1117-21
25. 25. Cannon CP, McCabe CH, Borzak S, et al. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Circulation 1998; 97: 340-9
26. 26. Murray CJL, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349: 1436-42